Identification of cuproptosis-related genes and immune infiltration in dilated cardiomyopathy
In an industry where brands constantly look for ways to deepen customer engagement and increase repeat purchases, this kind of product expansion strategy can be extremely valuable
While originally discovered in the 1970s, it has gained renewed interest in clinical and anti-aging circles due to its powerful ability to support skin repair, collagen production, and tissue remodeling at the cellular level
FTC AFFILIATE DISCLOSURE: This article contains affiliate links
Hydration & barrier function is important in the treatment of melasma as topical pigment correctors are frequently irritating
Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]
